New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration…

Source

Previous articlePharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
Next articleThe Agenda for Economic Analyses of Psychedelic-assisted Therapy